vs
Side-by-side financial comparison of KKR Real Estate Finance Trust Inc. (KREF) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
KKR Real Estate Finance Trust Inc. is the larger business by last-quarter revenue ($25.8M vs $18.3M, roughly 1.4× ROCKWELL MEDICAL, INC.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -101.7%, a 98.7% gap on every dollar of revenue. On growth, ROCKWELL MEDICAL, INC. posted the faster year-over-year revenue change (-25.6% vs -26.6%). Over the past eight quarters, ROCKWELL MEDICAL, INC.'s revenue compounded faster (-10.1% CAGR vs -18.8%).
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
KREF vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $25.8M | $18.3M |
| Net Profit | $-26.2M | $-554.0K |
| Gross Margin | — | 21.1% |
| Operating Margin | -105.1% | -2.2% |
| Net Margin | -101.7% | -3.0% |
| Revenue YoY | -26.6% | -25.6% |
| Net Profit YoY | -229.6% | 26.7% |
| EPS (diluted) | $-0.49 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $18.3M | ||
| Q3 25 | $25.3M | $15.9M | ||
| Q2 25 | $30.2M | $16.1M | ||
| Q1 25 | $31.3M | $18.9M | ||
| Q4 24 | $35.1M | $24.7M | ||
| Q3 24 | $37.0M | $28.3M | ||
| Q2 24 | $40.4M | $25.8M | ||
| Q1 24 | $39.1M | $22.7M |
| Q4 25 | $-26.2M | $-554.0K | ||
| Q3 25 | $13.8M | $-1.8M | ||
| Q2 25 | $-29.7M | $-1.5M | ||
| Q1 25 | $-4.9M | $-1.5M | ||
| Q4 24 | $20.3M | $-756.0K | ||
| Q3 24 | $-7.4M | $1.7M | ||
| Q2 24 | $25.8M | $343.0K | ||
| Q1 24 | $-3.1M | $-1.7M |
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | -105.1% | -2.2% | ||
| Q3 25 | 50.4% | -9.9% | ||
| Q2 25 | -101.3% | -8.4% | ||
| Q1 25 | -18.3% | -7.2% | ||
| Q4 24 | 55.8% | -2.1% | ||
| Q3 24 | -19.6% | 6.8% | ||
| Q2 24 | 63.3% | 2.0% | ||
| Q1 24 | -8.7% | -5.8% |
| Q4 25 | -101.7% | -3.0% | ||
| Q3 25 | 54.4% | -11.0% | ||
| Q2 25 | -98.5% | -9.3% | ||
| Q1 25 | -15.5% | -8.0% | ||
| Q4 24 | 57.7% | -3.1% | ||
| Q3 24 | -20.0% | 5.9% | ||
| Q2 24 | 63.9% | 1.3% | ||
| Q1 24 | -7.9% | -7.6% |
| Q4 25 | $-0.49 | $-0.01 | ||
| Q3 25 | $0.12 | $-0.05 | ||
| Q2 25 | $-0.53 | $-0.05 | ||
| Q1 25 | $-0.15 | $-0.04 | ||
| Q4 24 | $0.22 | $-0.02 | ||
| Q3 24 | $-0.19 | $0.04 | ||
| Q2 24 | $0.29 | $0.01 | ||
| Q1 24 | $-0.13 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.6M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $37.0M |
| Total Assets | $6.5B | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.6M | $10.7M | ||
| Q3 25 | $204.1M | $13.6M | ||
| Q2 25 | $107.7M | $12.5M | ||
| Q1 25 | $106.4M | $11.4M | ||
| Q4 24 | $104.9M | $15.7M | ||
| Q3 24 | $108.8M | $12.3M | ||
| Q2 24 | $107.2M | $11.9M | ||
| Q1 24 | $106.5M | $6.6M |
| Q4 25 | $1.2B | $37.0M | ||
| Q3 25 | $1.2B | $37.0M | ||
| Q2 25 | $1.2B | $30.4M | ||
| Q1 25 | $1.3B | $31.5M | ||
| Q4 24 | $1.3B | $32.6M | ||
| Q3 24 | $1.4B | $29.1M | ||
| Q2 24 | $1.4B | $23.5M | ||
| Q1 24 | $1.4B | $20.6M |
| Q4 25 | $6.5B | $57.1M | ||
| Q3 25 | $6.5B | $57.5M | ||
| Q2 25 | $6.8B | $52.6M | ||
| Q1 25 | $6.6B | $54.0M | ||
| Q4 24 | $6.4B | $59.2M | ||
| Q3 24 | $6.8B | $57.1M | ||
| Q2 24 | $7.1B | $53.0M | ||
| Q1 24 | $7.3B | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $72.3M | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $72.3M | $2.3M | ||
| Q3 25 | $18.5M | $-1.3M | ||
| Q2 25 | $21.1M | $1.8M | ||
| Q1 25 | $15.9M | $-3.5M | ||
| Q4 24 | $132.6M | $865.0K | ||
| Q3 24 | $49.1M | $4.3M | ||
| Q2 24 | $30.6M | $1.4M | ||
| Q1 24 | $34.5M | $-2.4M |
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | 1.19× | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KREF
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |